男受被做哭激烈娇喘gv视频,成人片免费网站,今天高清视频免费播放作文,欧美大片ppt免费

　　愛愛醫(yī)推薦原文閱讀：
　　A team from the Metastasis Research Laboratory (GIGA-Cancer/Liège University Hospital) has just published, in the journal Blood, their work demonstrating that the DMP1 protein has previously unsuspected anti-angiogenic activities which could be used for the development of new treatments against cancer, but also against diseases in which angiogenesis (the formation of new blood vessels) plays a major role, such as psoriasis, rheumatoid arthritis or diabetic retinopathy.
　　This discovery has also led to the registering of a patent by the three research protagonists: Doctor Akeila Bellahcène, a Senior Research Associate at the National Fund for Scientific Research (NFSR) who is running the project, Sophie Pirotte, a TELEVIE (NFSR) researcher, and Professor Vincent Castronovo, the Laboratory's Director.
　　Dr Bellahcène has been interested in SIBLINGs proteins for several years. They are a family of glycoproteins initially discovered for their role in the formation of bones and teeth. It is now over fifteen years ago that the Liège laboratory was the first to show that two of these proteins, bone sialoprotein (BSP) and osteopontin (OPN), are produced by cancer cells and probably play a role in the progression of these cancers, notably through their involvement in the formation of bone metastases. These original observations, confirmed by other international teams, opened the way for numerous projects studying the role played by these two proteins in cancer. Up until recently, DMP1, known above all for its role in teeth mineralisation, had not attracted attention in terms of a role in the development and progression of cancer.